Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1759 clinical trials
Safety Efficacy and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene

  • 33 views
  • 05 Mar, 2021
  • 29 locations
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response.

  • 0 views
  • 23 Jul, 2021
  • 49 locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

(compared with docetaxel) prolongs: 1) overall survival (OS); and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent

pembrolizumab
cancer
ct scan
pd-l1
measurable disease
  • 122 views
  • 23 Jul, 2021
  • 150 locations
Efficacy and Safety of Olaparib Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)

-free survival (PFS) using Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) in the treatment of CRC. Hypothesis 2 - Olaparib

chemotherapy regimen
solid tumour
systemic chemotherapy
colorectal adenocarcinoma
adenocarcinoma
  • 10 views
  • 18 Jul, 2021
  • 123 locations
  • 0 views
  • 23 Jul, 2021
  • 29 locations
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

lung carcinoma
durvalumab
  • 0 views
  • 21 Jul, 2021
  • 187 locations
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatment of advanced or metastatic HER2-positive breast cancer

  • 5 views
  • 25 May, 2021
  • 34 locations
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Open-label, dose-confirmation and cohort expansion, multicentre, Phase Ib/II study to assess the anti-tumour activity and safety of MEN1611 in combination with cetuximab for the treatment of patients with PIK3CA mutated metastatic colorectal cancer.

adenocarcinoma of colon
measurable disease
adenocarcinoma
cetuximab
metastasis
  • 2 views
  • 27 Jan, 2021
  • 39 locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

lung carcinoma
solid tumour
epidermal growth factor receptor
epidermal growth factor
measurable disease
  • 27 views
  • 04 Jul, 2021
  • 324 locations
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

The purpose of the study is to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a particular type of lung cancer. This type of cancer is called non-small …

lung carcinoma
cancer chemotherapy
epidermal growth factor receptor
epidermal growth factor
measurable disease
  • 0 views
  • 18 Jul, 2021
  • 44 locations